# CJC-1295 Ipamorelin Dosage in the Research Literature: Species, Routes, Half-Lives > CJC-1295 Ipamorelin dosage as studied in research: the doses given by species and route, the DAC vs no-DAC half-lives, and handling notes. No human dosing guidance. Studied doses and half-lives reported as research facts — not protocols, not instructions, not human guidance. ## Read this first This page reports the CJC-1295 Ipamorelin dosage figures that appear in the published research — and nothing more. It is a record of what investigators administered to laboratory animals and, for the CJC-1295 half, to healthy adults in early pharmacokinetic studies. It is not a protocol, not a recommendation, and not a guide for anyone to follow. Why the caution is more than boilerplate: there is no validated human dosing for ipamorelin and no human study of the fixed blend at all, so any "dose" you see circulating for the combination is community convention, not science. Doses below are stated only as the amount given to a particular species by a particular route, with the study attached. Two facts dominate everything here — the two halves have very different half-lives, and the combination's net exposure has never been measured. ## Cjc 1295 ipamorelin dosage: what was administered in studies The cjc 1295 ipamorelin dosage record is entirely single-component. For CJC-1295 with DAC, ascending single and multiple subcutaneous doses of 30 to 90 µg/kg were administered to healthy adults aged 21 to 61 in Phase 1 pharmacokinetic work; 30 or 60 µg/kg produced the 2- to 10-fold GH rise and multi-day IGF-1 elevation [1], and 60 or 90 µg/kg produced the ~7.5-fold trough-GH rise with preserved pulsatility [9]. In GHRH-knockout mouse studies, roughly 2 µg/day was used. For CJC-1295 no-DAC — Mod GRF (1-29) — there is no formal standalone human pharmacokinetic study; it is modelled in research protocols as a short pulsatile GHRH signal. For ipamorelin, dosing comes from rodent work: 100 µg/kg three times daily and 0.5 mg/kg/day in bone studies, and 0.01 to 1 mg/kg IV in gastrointestinal-motility studies, with roughly 1 µg/kg plateauing the GH response in rodent models. No validated human pharmacokinetic dose for ipamorelin has been published. These are research observations reported by species and route — not human guidance, and not a target for anyone. ## Half-lives: the two-clock problem The defining pharmacokinetic fact of this pairing is that its halves clear on different timescales. CJC-1295 with DAC has a half-life of roughly 6 to 8 days in humans — the albumin-bound peptide is detectable in rat plasma beyond 72 hours [5]. CJC-1295 no-DAC (Mod GRF 1-29) is on the order of minutes to about 30 minutes, like native GRF(1-29), because dipeptidyl peptidase-IV (DPP-IV) rapidly cleaves it; CJC-1295's amino-acid substitutions and DAC were specifically engineered to resist that cleavage [8]. Ipamorelin clears in under about 2 hours in rodent plasma, with peak GH response near 40 minutes post-dose and no validated human half-life published. The consequence is that "CJC-1295 Ipamorelin" can mean two very different exposure profiles depending on which CJC-1295 form is used: a multi-day GHRH background with the DAC version, or a short pulsatile GHRH signal with Mod GRF (1-29). The [cjc 1295 dac](/cjc-1295-dac) page works through what that distinction changes. ## Routes studied and handling notes Routes in the literature are predominantly subcutaneous and intravenous, with continuous subcutaneous infusion via osmotic minipump in rodent models and intranasal administration in some ipamorelin rodent pharmacokinetic work. The human CJC-1295 data is subcutaneous [1][9]. On handling, as a matter of laboratory practice: lyophilised (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks via asparagine deamidation, and the degradation products can be markedly less potent; agitation and repeated freeze-thaw are avoided. GHRH analogues undergo DPP-IV cleavage in plasma, which is why CJC-1295's substitutions and DAC matter [8]. This is standard laboratory-handling context only — it is not reconstitution instruction for human use, and no human dose or schedule is implied or endorsed anywhere on this site. ## Why no human dose appears here CJC-1295 (DAC) reached Phase 2 before development was discontinued; its Phase 1 data characterized pharmacokinetics and dose-response in healthy adults [1][9]. Ipamorelin was investigated, including a postoperative-ileus program, but was never advanced to approval. Critically, there is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 + ipamorelin combination — combination figures rest on each compound's individual literature plus general GHRH-plus-GHRP synergy data [3]. Because no regulatory body has established a human dose for either compound, and because the blend is entirely uncharacterized in humans, this site reports studied doses as historical research facts and stops there. The numbers above describe experiments. They are not a regimen, and converting them into one is outside both the evidence and the purpose of this digest. --- A mechanism-first reading of the CJC-1295 and ipamorelin record — two receptors, two timescales, every figure logged to its study and the untested fixed blend kept in plain view; no clinic behind the console and nothing here dosed, stacked, prescribed, or sold.